Venlafaxine, Paroxetine and Milnacipran for Major Depressive Disorder: A Pragmatic 24-Week Study

Hui-Yu Chuang ； Yun-Hsuan Chang ； Ling-Yi Cheng ； Yu-Shan Wang ； Shiou-Lan Chen ； Shih-Heng Chen ； Chun-Hsien Chu ； I-Hui Lee ； Po-See Chen ； Tzung-Lieh Yeh ； Yen-Kuang Yang ； Ru-Band Lu

《The Chinese Journal of Physiology》 57卷5期 (2014/10) Pp. 265-270

https://doi.org/10.4077/CJP.2014.BAC209

並列摘要

Major depressive disorder (MDD), one of the most common psychiatric disorders in the world, is a serious, recurrent and chronic mental disorder, which is associated with significant psychosocial disability and economic burden. Until recently, short-term effectiveness of antidepressants has been measured in terms of patients' response to the medications in significantly reduced depressive symptoms. Remission, a long-term elimination of symptoms and the restoration of normal functioning, has become the primary outcome of therapy. In the current study, the efficacy of three frequently prescribed antidepressants, venlafaxine (75-225 mg/day), paroxetine (20 mg/day) and milnacipran (100 mg/day), used in treating 249 MDD patients with Hamilton Rating Scale of Depression (HRSD_(17)) scores higher than 16 was compared. Each patient was evaluated at week 0, 1, 2, 4, 8, 12, 16, 20 and 24 in a 24-week open-label study. Eighty-two patients took venlafaxine, 97 took paroxetine and 70 patients took milnacipran. No significant differences were found between the three groups in the response condition (HRSD_(17) scores decreased more than 50%) after 24 weeks of follow-up. For remission, the paroxetine was the least efficacious medication than either the milnacipran (HRSD_(17) ≤ 7) or the venlafaxine (HRSD_(17) ≤ 5) by the last observation carried forward (LOCF) analysis. Our results suggest that the absence of depressive symptoms alone may not be an indicator for MDD remission, but the duration of absent depressive symptoms may be a better indicator.

並列關鍵字

milnacipran ； paroxetine ； remission ； response ； venlafaxine

參考文獻

Fang, Y.C.,Chou, C.T.,Pan, C.C.,Hsieh, Y.D.,Liang, W.Z.,Chao,D.,Tsai, J.Y.,Liao, W.C.,Kuo, D.H.,Shieh, P.,Kuo, C.C.,Jan, C.R.,Shaw, C.F.(2011).Paroxetine-induced Ca2+ movement and death in OC2 human oral cancer cells.Chinese J. Physiol.54,310-317.

Sahin, G.,Guner, I.,Yelmen, N.,Yaman, O.,Mengi, M.,Simsek, G.,Sipahi, S.(2011).Alterations of central hypercapnic respiratory response induced by acute central administration of serotonin reuptake inhibitor, fluoxetine.Chinese J. Physiol.54,356-366.

Su, S.W.,Cherng, C.F.,Lin, Y.C.,Yu, L.(2007).Prenatal exposure of bupropion may enhance agitation, anxiety responses, and sensitivity to cocaine effects in adult mice.Chinese J. Physiol.50,1-8.

Akerblad, A.C.,Bengtsson, F.,von Knorring, L.,Ekselius, L.(2006).Response, remission and relapse in relation to adherence in primary care treatment of depression: a 2-year outcome study.Int. Clin. Psychopharmacol.21,117-124.

Angst, J.(1999).Major depression in 1998: are we providing optimal therapy?.J. Clin. Psychiatry.60(Suppl 6),5-9.